TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00980031
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg PO daily (QD)for 6 months
Study: NCT00980031
Drug: Lactose Tablet
Normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose tablet
Study: NCT01044264
Drug: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT01044264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01724450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo similar to the carvedilol up titration but wit no active drug.
Study: NCT03437070
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously per protocol on Day 1 for 21-day cycles.
Study: NCT02859142
Drug: NicodermCQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches provided over 12 week participation
Study: NCT02859142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
Study: NCT02565511
Drug: CNP520
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
Study: NCT02057887
Drug: HM10660A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01230593
Drug: Hot Compress plus Tobramycin Drops and Ointment
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
Study: NCT01230593
Drug: Hot compress plus Tobramycin/Dexamethasone Drops and Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
Study: NCT03018626
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
Study: NCT03018626
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide(750 mg/m2)/dayg IV on days 5
Study: NCT03018626
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
Study: NCT03018626
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
Study: NCT01449591
Drug: Noritate® 1% cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00746837
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
Study: NCT00746837
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg od, 12 days
Study: NCT00746837
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg od, 12 days
Study: NCT01227889
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg twice daily
Study: NCT01055743
Drug: Fluorouracil Implants
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Implanted during the surgical treatment
Study: NCT00620308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water (the vehicle)
Study: NCT05321524
Drug: OCA 0.1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily.
Study: NCT05321524
Drug: OCA 1.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily.
Study: NCT00135954
Drug: Cyclophosphamide and steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of difference in time of start of therapy
Study: NCT03221582
Drug: EBR/GZR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
Study: NCT01795222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
Study: NCT02479412
Drug: 250 µg AZD7594 once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study: NCT02479412
Drug: 58 µg AZD7594 once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study: NCT02479412
Drug: Placebo once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study: NCT02264067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg PO BID
Study: NCT00783536
Drug: DMARDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00532961
Drug: Loteprednol etabonate 0.5% and tobramycin 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
Study: NCT00532961
Drug: Dexamethasone 0.1% and tobramycin 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
Study: NCT00953043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication given for three days
Study: NCT03824925
Drug: Placebo oral Zinc capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
Study: NCT03824925
Drug: Zinc Sulfate 220 MG
Normalized name: zinc sulfate 220 MG
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
Study: NCT00418834
Drug: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (unspecified) daily for 12 weeks
Study: NCT02242227
Drug: Serevent® Diskus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242227
Drug: Placebo (HandiHaler®)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242227
Drug: Placebo (Diskus®)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00352755
Drug: Intraperitoneal 5FU
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00352755
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00478725
Drug: GW786034, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 800 mg
Study: NCT00478725
Drug: GW786034, IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, 5 mg
Study: NCT00478725
Drug: GW786034, radiolabeled oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 400 mg radiolabeled
Study: NCT01907984
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00734344
Drug: Emtricitibine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg once daily
Study: NCT03443960
Drug: TNX-102 SL 5.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
Study: NCT03434119
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
Study: NCT01184014
Drug: Complete Insulin Orders
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-part insulin which includes background, meal-time and correction factor
Study: NCT00745017
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
Study: NCT02528214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Study: NCT02528214
Drug: Oral corticosteroid therapy (prednisone/prednisolone)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT02528214
Drug: Inhaled corticosteroid (ICS) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
Study: NCT03862404
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: See previous description
Study: NCT03862404
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: See previous descreption
Study: NCT00102895
Drug: CP-724,714
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00489450
Drug: SK3530
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00153049
Drug: Telmisartan + Hydrochlorothiazide
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01490346
Drug: Initiation of anti-retroviral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
Study: NCT01562574
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
Study: NCT03799926
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Study: NCT03799926
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Study: NCT01304836
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV \& oral
Study: NCT01568047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily
Study: NCT01568047
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 - 5 mg single-dose
Study: NCT01568047
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 - 15 mg single-dose
Study: NCT01568047
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 9-1067 - 30 mg single-dose
Study: NCT01568047
Drug: Levodopa/Carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg Carbidopa 25 mg
Study: NCT01568047
Drug: Levodopa/Benzerazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg Benzerazide 25 mg
Study: NCT00817089
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT02277782
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02127801
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02962830
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-amniotic injection of 10 micrograms of Sufentanil
Study: NCT00737841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
Study: NCT03593668
Drug: Benaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH
Study: NCT03364335
Drug: Leu Met Sil 1.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leu 1100 mg + Met 500mg + 1mg Sil BID
Study: NCT00746603
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
Study: NCT03364335
Drug: Leu Met Sil 4.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leu 1100 mg + Met 500mg + 4mg Sil BID
Study: NCT03364335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00728312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
Study: NCT03591744
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01510847
Drug: Andriol Testocaps
Normalized name: Pri-Andriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 40mg, Twice a day, 30days
Study: NCT02324491
Drug: ZGN-440 for Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
Study: NCT02324491
Drug: ZGN-440 Placebo for Injectable Suspension
Normalized name: placebo 440 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
Study: NCT01665235
Drug: ACEI / ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
Study: NCT00326378
Drug: CCRT arm without consolidation chemotherapy
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
Study: NCT02807064
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,5 ml per os all days for 2 months
Study: NCT00479024
Drug: iodinated contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
Study: NCT00562783
Drug: Vitaliver
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00562783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00948818
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study: NCT00130806
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02320695
Drug: Antibiotic/Pain Relieving Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03710941
Drug: REGN2477+REGN1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, sequential, repeat-dose Intravenous (IV) or matching placebo
Study: NCT03710941
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, sequential, repeat-dose Intravenous (IV)
Study: NCT00663728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02529241
Drug: Group 2:LCB01-0371
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg
Study: NCT00488579
Drug: Two policies of iron prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
Study: NCT02330549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching CVC administered orally once daily and taken every morning with food.
Study: NCT02696915
Drug: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
Study: NCT01490749
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
Study: NCT01490749
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive two cycles of XELOX.
Study: NCT02293018
Drug: 0.75% (w/w) MTC896 Gel Once Daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02293018
Drug: 0.75% (w/w) MTC896 Gel Twice Daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02293018
Drug: 1.5% (w/w) MTC896 Gel Once Daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04380961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo IV single dose infusion on Day 1.
Study: NCT00914602
Drug: Sinemet 25-100 Oral Tablet
Normalized name: Sinemet 25-100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
Study: NCT01724983
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00738842
Drug: AZD6140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken bid for 5 days
Study: NCT00738842
Drug: Placebo to match AZD6140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken bid for 5 days
Study: NCT03070522
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02599792
Drug: Placebo for CTP-656
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00740545
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women inject ourselves every days with placebo
Study: NCT03859323
Drug: SHP681
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC injection of SHP681 in the abdomen.
Study: NCT02094872
Drug: MEK 162 therapy or molecularly targeted therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: molecularly targeted therapy, MEK 162 therapy
Study: NCT02194049
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00051558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo, daily, 36 months
Study: NCT00051558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection placebo, daily, 36 months
Study: NCT03779035
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250mg/m2
Study: NCT03785496
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
Study: NCT02364947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed; tablets, orally
Study: NCT02536170
Drug: L-arginine Loading Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
Study: NCT03230162
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
Study: NCT00509496
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day x 2 days intravenous
Study: NCT02042729
Drug: E2022- Current Formula Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.
Study: NCT02042729
Drug: E2022- New Formula Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.
Study: NCT02042729
Drug: E2022 Matching Placebo- Current Formula Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02042729
Drug: E2022 Matching Placebo- New Formula Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02583802
Drug: Ear pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.